A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN CLAIMS DATA
Author(s)
Shrestha A1, Eldar-Lissai A2, Wu Y1, Batt K3, Krishnan S2, Lakdawalla D4
1Precision Health Economics, Los Angeles, CA, USA, 2Biogen Idec, Cambridge, MA, USA, 3Wake Forest School of Medicine, Winston-Salem, NC, USA, 4University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Hemophilia-related bleeding events are difficult to quantify. Insurance claims’ data may capture the information, but there is no robust methodology to identify these events. METHODS: Using 2004-2012 Truven Health MarketScan commercial claims database (coverage of >30 million employees in th United States), we evaluated males under age 65 having ≥1 inpatient/≥2 outpatient claims 30-day apart for hemophilia A or B (ICD-9: 286.0, 286.1), and ≥1 pharmacy claim for clotting factors VIII or IX with ≥12 months continuous enrollment from first hemophilia treatment were selected. Bleeding events were identified using ICD-9 codes for hemarthrosis, hematoma or other acute bleeds in inpatient/outpatient claims. Hemophilia treatment guidelines recommend 1-14 day treatment depending on bleeding severity. We explored aggregating claims within varying time windows (1, 7, 10, and 14 days) to capture a single bleeding event and assessed sensitivity of the time differences using pairwise rank correlations. RESULTS: We identified 2,425 and 269 hemophilia A and B patients. Using a 7-day window, average annual bleeds ((total bleeds ÷ patient-months)*12) among patients with ≥ 1 bleed equaled 2.31 (range: 1-33) for hemophilia A and 1.92 (range: 1-18) for hemophilia B. Results were similar for a 10-day window (hemophilia A: 2.21 (1-31), hemophilia B: 1.81 (1–14)) and 14-day window (hemophilia A: 2.10 (1–24), hemophilia B: 1.69 (1–12) ) ). A 1-day window produced somewhat higher numbers (hemophilia A: 2.99 (1-66), hemophilia B: 2.72 (1-45)), but pairwise rank correlation remained high across the four assumptions (coefficients ≥ 0.99, p-values <0.01 for both disease types). Frequencies are comparable to a large US-based study reporting bleeds in moderately-severe patients, albeit smaller than studies of severe patients. CONCLUSIONS: Claims data can be utilized to construct stable, robust indices of bleeding events in hemophilia patients, permitting reliable studies of factors influencing bleeding frequency and healthcare burden.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
DB2
Topic
Real World Data & Information Systems, Study Approaches
Topic Subcategory
Reproducibility & Replicability
Disease
Systemic Disorders/Conditions